Search results: (10000)
News Comorbidities of Migraine and Their Impact on Pain Frequency and Intensity
The MAST study, published in March of this year in the prestigious The Journal of Headache and Pain, focused on the occurrence of associated diseases in patients with migraine. What is the prevalence of individual comorbidities and which of them are associated with changes in pain intensity and frequency?
News 6-year data from the ECHELON-1 study: How does combining brentuximab vedotin with chemotherapy affect overall survival of previously untreated cHL patients?
At this year's annual congress of the European Hematology Association (EHA), results from the analysis of 6-year data from the international randomized open-label phase III ECHELON-1 study on overall survival of patients with classical Hodgkin lymphoma (cHL) stage III/IV who received a combination of brentuximab vedotin with chemotherapy in the first-line treatment were presented, among other findings.
News How to Care for Dialysis Patients in the Times of COVID-19
More than 2 million people worldwide undergo maintenance hemodialysis in outpatient centers. Effective prevention of the spread of infection caused by the SARS-CoV-2 coronavirus within the care provided by hemodialysis centers is essential for the smooth provision of dialysis to patients with end-stage renal disease. The following work from experts in Boston is based on their experiences as well as recommendations from the American Society of Nephrology (ASN) and the Centers for Disease Control and Prevention (CDC).
News Post hoc Analysis of the FRAME Study – Romosozumab in the Treatment of Osteoporosis in the European Population
An interesting finding from the FRAME study, which evaluated the treatment of postmenopausal women with osteoporosis using romosozumab, was the significant differences in fracture incidence among patients from various geographic regions. The following post hoc analysis specifically focused on data from European women.
News CASE STUDY: Surgical Procedure in an Adolescent Patient with Severe Hemophilia A on Emicizumab Prophylaxis
This case study is narrated by MUDr. Bohumír Blažek from the Clinic of Pediatric Medicine at LF OU and FN Ostrava. The patient is a 17-year-old boy with severe hemophilia A. Several months prior to the procedure under discussion, he was switched from prophylactic factor VIII administration to emicizumab prophylaxis. Subsequently, an extraction of all four molars was planned for orthodontic reasons. The case study describes the hematologist's approach to the procedure and the subsequent healing process.
News Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC
A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors – brigatinib, followed by lorlatinib – in real-world clinical practice.
News Cariprazine − a Cardiometabolically Friendly Antipsychotic
Part of the 63rd Czech-Slovak Psychopharmacological Conference, held online from January 15−16, 2021, featured a lecture by Prof. MUDr. Jiří Masopust, Ph.D., from the Psychiatric Clinic of the Faculty of Medicine, Charles University and University Hospital Hradec Králové, titled “Cariprazine: a Cardiometabolically Friendly Antipsychotic”.
News Fresh from ASH 2021: Promising results of the combination of azacitidine with venetoclax and magrolimab in the treatment of AML
Dr. Naval Daver and his colleagues from the Anderson Cancer Center in Houston presented an oral report during the December congress of the American Society of Hematology (ASH 2021) about a phase Ib/II study that evaluated the effects of the combination of azacitidine (AZA) + venetoclax (VEN) + magrolimab (magro) in various types of patients with acute myeloid leukemia (AML) – newly diagnosed in older or unfit individuals, high-risk, or relapsed/refractory cases (R/R AML).
News TTR amyloidosis – at the crossroads of cardiology and orthopedics
In wild-type transthyretin amyloid cardiomyopathy, extra-cardiac symptoms occur in addition to cardiac symptoms. Common and characteristic orthopedic manifestations include bilateral carpal tunnel syndrome, spinal canal stenosis in the lumbar region, or atraumatic rupture of the m. biceps brachii tendon. These extra-cardiac symptoms often precede the actual heart involvement. Recognizing them can thus increase diagnostic suspicion for cardiac amyloidosis and help in the timely establishment of the correct diagnosis and initiation of specific treatment. For example, even a rheumatologist or orthopedist can direct an elderly patient with an otherwise unexplained constellation of musculoskeletal symptoms to cardiology examination early, thereby significantly improving the patient's prognosis.
News Candesartan is beneficial in heart failure with mildly reduced ejection fraction
Analysis of data from the CHARM study showed that in patients with heart failure with mildly reduced ejection fraction (HFmrEF 0.40–0.49), candesartan compared to placebo reduces the risk of death from cardiovascular (CV) causes or hospitalization for heart failure similarly to patients with reduced ejection fraction (HFrEF < 0.40).
News Potential of Aloe to Reduce Severity of Symptoms in Patients with IBS − What Emerged from the Analysis of Fecal Microflora and Metabolite Profiles?
Current treatment options for irritable bowel syndrome (IBS − irritable bowel syndrome) are relatively limited. This increases interest in complementary and alternative therapy options with plant preparations. One modality used to alleviate IBS symptoms is Aloe barbadensis Mill. The aim of a clinical study by Swedish researchers was to assess the effect of aloe on IBS symptoms compared to a control treatment with inulin.
News Changes in Blood Count as Possible Prognostic Markers of Response to Panitumumab in Patients with mCRC
As part of the VALENTINO study with panitumumab in patients with metastatic colorectal cancer without RAS mutation, the connection between certain blood count parameters associated with inflammation and patient prognosis was investigated.
News Effect of Nuclear Magnetic Resonance Therapy in Patients with Osteoarthritis
Osteoarthritis represents the most common joint disease in adults, with its incidence and prevalence increasing with age. With the overall aging of the population, it is becoming a significant medical as well as social problem. Due to the growing number of cases, new modalities are being sought for current therapeutic procedures, including nuclear magnetic resonance therapy, whose effect has been verified by an extensive clinical study.
News Neutralizing Antibodies Against Emicizumab – Detailed Analysis Based on a Case Study
Japanese authors investigated the mechanism of reduced efficacy of emicizumab in an adult patient with hemophilia A and an inhibitor, whose treatment was discontinued due to repeated bleeding episodes with prolonged aPTT.
News Transfer of Microbiome from Mother to Child: A Key but Fragile Process
How does the transfer of gut microbiota between mother and child occur? Is this transfer clinically significant, and what factors can disrupt it? These questions are addressed in a 2019 review article by Dutch microbiologists.
News Summary of New American Recommendations for Heart Failure Management
This year, the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) released joint recommendations for the diagnosis and treatment of heart failure in clinical practice. These new guidelines replace the previous recommendations from 2013 and their 2017 update. We summarize the 10 key points to remember as outlined by the authors of the new guidelines and focus on the treatment of the subgroup of patients with heart failure with preserved ejection fraction (HFpEF).
News Direct Comparison of the Efficacy and Safety of Anti-EGFR Antibodies in the Combined Therapy of Chemotherapy-Refractory Metastatic Colorectal Cancer
The combination of anti-EGFR therapy with irinotecan has brought benefits to patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) in clinical studies. Results of a study directly comparing the efficacy of two different EGFR inhibitors, panitumumab and cetuximab, in combination with irinotecan have been published in the European Journal of Cancer.
News Are All Patients Really Suitable for Thromboprophylaxis Treated This Way?
A study published this year aimed to assess how often the risk of VTE is assessed in routine clinical practice in internally ill patients, what proportion of patients are suitable for thromboprophylaxis, and how many actually receive this treatment.
News Development and Benefits of Intestinal Gel LECIG for Patients with Parkinson's Disease
Patients with advanced Parkinson's disease, for whom the current regimen of orally and transdermally administered medications is insufficient for symptom relief, now have a new treatment option. It involves the continuous administration of an intestinal gel that combines three effective antiparkinsonian drugs.
News Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).
News Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in which the authors thoroughly examined current knowledge on the epidemiology, pathophysiology, diagnosis, and treatment of heart failure with preserved ejection fraction of the left ventricle (HFpEF). Recent studies in this heterogeneous disease suggest the importance of carefully determining the HFpEF phenotype in a given patient based on pathophysiology, which enables better individualization of treatment. The authors also reflect on the success of gliflozins in treating HFpEF and how HFpEF pharmacotherapy can be further improved.
News Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction
Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of death from cardiovascular causes or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetic and non-diabetic patients. The aim of the EMPEROR-Reduced clinical study was to supplement data on the effect of empagliflozin on the incidence of heart failure worsening events requiring hospitalization or outpatient treatment.
News Subcutaneous pdC1-INH in Patients with Hereditary Angioedema in Real-World Practice
Italian authors published a series of cases of patients with hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE) with long-term prophylaxis using human plasma-derived C1 inhibitor concentrate (pdC1-INH) in subcutaneous form. They supplement the results of the placebo-controlled COMPACT study, in which s.c. pdC1-INH reduced the frequency of attacks, with insights from real-world practice in 5 patients treated at the angioedema therapy center in Milan, Italy.
News Are there mutual interactions between candesartan and amlodipine in the combination therapy of hypertension?
Monotherapy is often insufficient in the treatment of hypertension; however, combining antihypertensives with different mechanisms of action can be complicated by their mutual interactions. Therefore, a study by South Korean authors examined the pharmacokinetic interactions between candesartan and amlodipine, substances that are commonly used together in combined treatment.